Clinical Cancer Research, Vol 4, Issue 12 2939-2947, Copyright © 1998 by American Association for Cancer Research

ARTICLES

Basic fibroblast growth factor receptors and their prognostic value in human breast cancer

VD Blanckaert, M Hebbar, MM Louchez, MO Vilain, ME Schelling and JP Peyrat
Laboratoire d'Oncologie Moleculaire Humaine, Centre Oscar Lambret, Lille, France.

We performed a saturation binding study with 125I-labeled FGF (fibroblast growth factor)-2 in a nonselected series of 250 human primary breast cancers. Two hundred twenty-five breast cancer biopsies possessed bFGFR (basic FGF receptor). The median dissociation constant was 0.35 nM (range, 0.014-1.9), and the median concentration was 1126 fmol/mg protein (range, 49-7328). FGFR-1 was localized, using a specific monoclonal antibody, in cancerous cells and in epithelial cells in normal breast or in benign tumors. In all of the tissues studied, light stromal cell staining was also observed. Thus, the localization of FGFR-1 in carcinoma cells supports the hypothesis that an important part of FGF-2 binding reflects binding to FGFR-1. bFGFR concentrations were positively correlated to estrogen receptor and progesterone receptor levels. Cox univariate analyses showed that the bFGFR (> or = upper quartile) was associated to longer relapse-free survival [P = 0.004; RR (risk ratio), 0.46] and overall survival (P = 0.001; RR, 0.35); age, estrogen receptor levels, progesterone receptor levels, node involvement, tumor diameter, and histoprognostic grading were prognostic, also. In Cox multivariate analyses, only the bFGFR, age, node involvement, and histoprognostic grading were prognostic factors; the bFGFR was associated with longer relapse-free survival (P = 0.03; RR, 0.4) and overall survival (P = 0.009; RR, 0.3). The present study confirms that FGF could be an important regulator of human breast cancer growth and that patients with a high level of bFGFR had a better prognosis.

This article has been cited by other articles:

				M. A. Villalona-Calero, G. A. Otterson, M. G. Wientjes, F. Weber, T. Bekaii-Saab, D. Young, A. J. Murgo, R. Jensen, T.-K. Yeh, Y. Wei, et al. Noncytotoxic suramin as a chemosensitizer in patients with advanced non-small-cell lung cancer: a phase II study Ann. Onc., July 15, 2008; (2008) mdn412v1. [Abstract] [Full Text] [PDF]

				F. Revillion, M. Charlier, V. Lhotellier, L. Hornez, S. Giard, M.-C. Baranzelli, J. Djiane, and J.-P. Peyrat Messenger RNA expression of leptin and leptin receptors and their prognostic value in 322 human primary breast cancers. Clin. Cancer Res., April 1, 2006; 12(7 Pt 1): 2088 - 2094. [Abstract] [Full Text] [PDF]

				S. M. Duplan, Y. Theoret, and R. Kenigsberg Antitumor Activity of Fibroblast Growth Factors (FGFs) for Medulloblastoma May Correlate with FGF Receptor Expression and Tumor Variant Clin. Cancer Res., January 1, 2002; 8(1): 246 - 257. [Abstract] [Full Text] [PDF]

				S. Descamps, V. Pawlowski, F. Revillion, L. Hornez, M. Hebbar, B. Boilly, H. Hondermarck, and J.-P. Peyrat Expression of Nerve Growth Factor Receptors and Their Prognostic Value in Human Breast Cancer Cancer Res., June 1, 2001; 61(11): 4337 - 4340. [Abstract] [Full Text] [PDF]

				M. Cuny, A. Kramar, F. Courjal, V. Johannsdottir, B. Iacopetta, H. Fontaine, J. Grenier, S. Culine, and C. Theillet Relating Genotype and Phenotype in Breast Cancer: An Analysis of the Prognostic Significance of Amplification at Eight Different Genes or Loci and of p53 Mutations Cancer Res., February 1, 2000; 60(4): 1077 - 1083. [Abstract] [Full Text]